<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Drug Discovery & KRAS Inhibition | Cristea Lab</title>
    <link rel="stylesheet" href="../styles.css">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        .research-page {
            margin-top: 100px;
            padding: 3rem 0;
        }
        .research-hero {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: 4rem 0;
            text-align: center;
            margin-bottom: 4rem;
        }
        .research-hero h1 {
            font-size: 3rem;
            margin-bottom: 1rem;
        }
        .research-hero p {
            font-size: 1.3rem;
            max-width: 800px;
            margin: 0 auto;
            opacity: 0.9;
        }
        .research-section {
            margin-bottom: 4rem;
        }
        .research-section h2 {
            font-size: 2.5rem;
            color: var(--primary-color);
            margin-bottom: 2rem;
            border-bottom: 3px solid var(--primary-color);
            padding-bottom: 0.5rem;
        }
        .project-card {
            background: white;
            border-radius: 15px;
            box-shadow: var(--shadow);
            padding: 2.5rem;
            margin-bottom: 2rem;
            border-left: 5px solid var(--accent-color);
            transition: var(--transition);
        }
        .project-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 15px 35px rgba(0, 0, 0, 0.15);
        }
        .project-card h3 {
            font-size: 1.8rem;
            color: var(--primary-color);
            margin-bottom: 1rem;
        }
        .project-card h4 {
            font-size: 1.3rem;
            color: var(--accent-color);
            margin-bottom: 1rem;
            font-weight: 600;
        }
        .project-description {
            font-size: 1.1rem;
            line-height: 1.7;
            margin-bottom: 1.5rem;
        }
        .project-details {
            background: var(--bg-light);
            padding: 1.5rem;
            border-radius: 10px;
            margin: 1.5rem 0;
        }
        .project-details h5 {
            color: var(--primary-color);
            margin-bottom: 1rem;
        }
        .methodology-list {
            list-style: none;
            padding: 0;
        }
        .methodology-list li {
            padding: 0.5rem 0;
            border-bottom: 1px solid #eee;
        }
        .methodology-list li:last-child {
            border-bottom: none;
        }
        .methodology-list li::before {
            content: 'ðŸ”¬';
            margin-right: 0.5rem;
        }
        .impact-highlight {
            background: linear-gradient(135deg, #f8f9fa, #e9ecef);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid var(--secondary-color);
            margin: 2rem 0;
        }
        .impact-highlight h4 {
            color: var(--secondary-color);
            margin-bottom: 1rem;
        }
        .tech-stack {
            display: flex;
            flex-wrap: wrap;
            gap: 0.5rem;
            margin: 1rem 0;
        }
        .tech-tag {
            background: var(--primary-color);
            color: white;
            padding: 0.3rem 0.8rem;
            border-radius: 15px;
            font-size: 0.9rem;
            font-weight: 500;
        }
        .drug-highlight {
            background: linear-gradient(135deg, #fff3e0, #ffe0b2);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #ff9800;
            margin: 2rem 0;
        }
        .drug-highlight h4 {
            color: #f57c00;
            margin-bottom: 1rem;
        }
        .resistance-analysis {
            background: linear-gradient(135deg, #fce4ec, #f8bbd9);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #e91e63;
            margin: 2rem 0;
        }
        .resistance-analysis h4 {
            color: #c2185b;
            margin-bottom: 1rem;
        }
        .screen-results-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1.5rem;
            margin: 2rem 0;
        }
        .screen-result-card {
            background: white;
            padding: 1.5rem;
            border-radius: 10px;
            box-shadow: var(--shadow);
            border-top: 4px solid var(--accent-color);
            text-align: center;
        }
        .target-discovery {
            background: linear-gradient(135deg, #e3f2fd, #bbdefb);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #2196f3;
            margin: 2rem 0;
        }
        .target-discovery h4 {
            color: #1976d2;
            margin-bottom: 1rem;
        }
    </style>
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="nav-container">
            <div class="nav-brand">
                <h1>Cristea Lab</h1>
                <span class="nav-subtitle">Computational Cancer Research</span>
            </div>
            <ul class="nav-menu">
                <li><a href="../index.html" class="nav-link">Home</a></li>
                <li><a href="../index.html#research" class="nav-link">Research</a></li>
                <li><a href="../team.html" class="nav-link">Team</a></li>
                <li><a href="../publications.html" class="nav-link">Publications</a></li>
                <li><a href="../index.html#software" class="nav-link">Software</a></li>
                <li><a href="../index.html#contact" class="nav-link">Contact</a></li>
            </ul>
            <div class="nav-toggle">
                <span class="bar"></span>
                <span class="bar"></span>
                <span class="bar"></span>
            </div>
        </div>
    </nav>

    <!-- Research Page Content -->
    <div class="research-page">
        <!-- Hero Section -->
        <div class="research-hero">
            <div class="container">
                <h1>Drug Discovery & KRAS Inhibition</h1>
                <p>
                    Pioneering drug perturbation analysis through CRISPR screens and cell surfaceome analysis 
                    to identify novel therapeutic targets and overcome resistance to KRAS inhibitors in pancreatic cancer.
                </p>
            </div>
        </div>

        <div class="container">
            <!-- Overview -->
            <div class="research-section">
                <h2>Research Overview</h2>
                <div class="project-description">
                    Our drug discovery research focuses on understanding and overcoming resistance to KRAS inhibitors, 
                    one of the most promising recent advances in pancreatic cancer treatment. We employ cutting-edge 
                    CRISPR screening technologies and proteomics approaches to identify vulnerabilities in KRAS-driven 
                    cancers and develop next-generation therapeutic strategies.
                </div>
                
                <div class="drug-highlight">
                    <h4>KRAS: The "Undruggable" Target</h4>
                    <p>
                        KRAS has long been considered "undruggable" due to its smooth protein surface and high affinity 
                        for its substrate. Recent breakthroughs in KRAS inhibitor development have opened new therapeutic 
                        possibilities for pancreatic cancer patients, but resistance inevitably emerges. Our research 
                        aims to stay ahead of resistance by understanding its mechanisms and developing combination 
                        strategies to prevent or overcome it.
                    </p>
                </div>
            </div>

            <!-- Project A: Resistance Mechanisms -->
            <div class="research-section">
                <h2>Project A: Mechanisms of KRAS Inhibition Resistance</h2>
                <div class="project-card">
                    <h3>Whole Exome Sequencing and Bulk Genomics Analysis</h3>
                    <div class="project-description">
                        We perform comprehensive genomic analysis of pancreatic cancer models and patient samples that 
                        have developed resistance to KRAS inhibitors. This work identifies genetic alterations that 
                        drive resistance and reveals potential therapeutic targets to overcome resistance mechanisms.
                    </div>
                    
                    <div class="project-details">
                        <h5>Resistance Analysis Pipeline</h5>
                        <ul class="methodology-list">
                            <li>Longitudinal whole exome sequencing of resistant tumor samples</li>
                            <li>Comparative genomics between sensitive and resistant cell lines</li>
                            <li>Identification of resistance-associated mutations and copy number alterations</li>
                            <li>Pathway analysis of resistance mechanisms</li>
                            <li>Validation of resistance drivers through functional studies</li>
                        </ul>
                    </div>

                    <div class="resistance-analysis">
                        <h4>Key Resistance Mechanisms Identified</h4>
                        <p>
                            Our analysis has revealed multiple pathways through which pancreatic cancers can escape 
                            KRAS inhibition, including reactivation of downstream signaling pathways, activation 
                            of alternative oncogenic drivers, and metabolic reprogramming. Understanding these 
                            mechanisms enables the development of rational combination therapies.
                        </p>
                    </div>

                    <div class="project-details">
                        <h5>Clinical Translation</h5>
                        <p>
                            We work closely with clinical teams to analyze samples from patients who develop resistance 
                            to KRAS inhibitors. This real-world data validation ensures that our laboratory findings 
                            are clinically relevant and can inform patient treatment decisions.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Whole Exome Sequencing</span>
                        <span class="tech-tag">Resistance Mechanisms</span>
                        <span class="tech-tag">Comparative Genomics</span>
                        <span class="tech-tag">Pathway Analysis</span>
                        <span class="tech-tag">Clinical Validation</span>
                    </div>
                </div>
            </div>

            <!-- Project B: CRISPR Screens -->
            <div class="research-section">
                <h2>Project B: CRISPR Screening of KRAS Inhibitors</h2>
                <div class="project-card">
                    <h3>Pan-RAS and KRAS Mutant-Selective Inhibition Analysis</h3>
                    <div class="project-description">
                        We conduct large-scale CRISPR knockout screens to identify genetic dependencies and resistance 
                        mechanisms for both pan-RAS inhibitors and KRAS mutant-selective inhibitors in pancreatic 
                        cancer cell lines. This systematic approach reveals vulnerabilities that can be exploited 
                        for combination therapies.
                    </div>

                    <div class="project-details">
                        <h5>CRISPR Screen Design</h5>
                        <ul class="methodology-list">
                            <li>Genome-wide CRISPR knockout screens in multiple pancreatic cancer cell lines</li>
                            <li>Comparative analysis of pan-RAS vs. mutant-selective inhibitor responses</li>
                            <li>Time-course analysis to identify early and late resistance mechanisms</li>
                            <li>Drug dose response screening to identify synergistic combinations</li>
                            <li>Functional validation of top candidate genes</li>
                        </ul>
                    </div>

                    <div class="screen-results-grid">
                        <div class="screen-result-card">
                            <i class="fas fa-bullseye" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Synthetic Lethal Targets</h4>
                            <p>Genes essential only in KRAS mutant context</p>
                        </div>
                        <div class="screen-result-card">
                            <i class="fas fa-shield-alt" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Resistance Genes</h4>
                            <p>Genes that protect against KRAS inhibition</p>
                        </div>
                        <div class="screen-result-card">
                            <i class="fas fa-link" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Combination Targets</h4>
                            <p>Genes for synergistic drug combinations</p>
                        </div>
                        <div class="screen-result-card">
                            <i class="fas fa-route" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Pathway Dependencies</h4>
                            <p>Essential signaling pathways in resistance</p>
                        </div>
                    </div>

                    <div class="project-details">
                        <h5>Drug Classes Analyzed</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>G12C-specific inhibitors</strong> - AMG510 (sotorasib), MRTX849 (adagrasib)</li>
                            <li><strong>Pan-KRAS inhibitors</strong> - RMC-6236, next-generation compounds</li>
                            <li><strong>Downstream targets</strong> - MEK, ERK, PI3K/AKT pathway inhibitors</li>
                            <li><strong>Combination approaches</strong> - KRAS + CDK4/6, KRAS + autophagy, etc.</li>
                        </ul>
                    </div>

                    <div class="impact-highlight">
                        <h4>Therapeutic Innovation</h4>
                        <p>
                            Our CRISPR screens have identified several promising combination therapy opportunities 
                            that are now being tested in preclinical models and clinical trials. These rational 
                            combinations have the potential to prevent resistance and improve patient outcomes 
                            compared to KRAS inhibitor monotherapy.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">CRISPR Screening</span>
                        <span class="tech-tag">Pan-RAS Inhibitors</span>
                        <span class="tech-tag">Synthetic Lethality</span>
                        <span class="tech-tag">Combination Therapy</span>
                        <span class="tech-tag">Drug Synergy</span>
                    </div>
                </div>
            </div>

            <!-- Project A: PhageDisplay Screening -->
            <div class="research-section">
                <h2>Project A: PhageDisplay Antibody Screening</h2>
                <div class="project-card">
                    <h3>Large-scale Antibody Screening for KRAS Inhibition</h3>
                    <div class="project-description">
                        We employ PhageDisplay technology to screen large antibody libraries for novel binding partners 
                        and therapeutic targets in KRAS-driven pancreatic cancer. This approach enables the discovery 
                        of cell surface proteins that can be targeted with antibody-drug conjugates or immunotherapies.
                    </div>

                    <div class="project-details">
                        <h5>PhageDisplay Screening Pipeline</h5>
                        <ul class="methodology-list">
                            <li>Large-scale phage display library screening on pancreatic cancer cell lines</li>
                            <li>Differential screening between KRAS mutant and wild-type cells</li>
                            <li>Identification of cell surface proteins enriched in resistant populations</li>
                            <li>Antibody affinity maturation and characterization</li>
                            <li>Functional validation of antibody-target interactions</li>
                        </ul>
                    </div>

                    <div class="target-discovery">
                        <h4>Novel Target Discovery</h4>
                        <p>
                            PhageDisplay screening has identified several previously unknown cell surface proteins 
                            that are specifically expressed or upregulated in KRAS-driven pancreatic cancers. 
                            These targets represent opportunities for developing highly specific antibody-drug 
                            conjugates that can deliver cytotoxic payloads directly to cancer cells.
                        </p>
                    </div>

                    <div class="project-details">
                        <h5>Antibody-Drug Conjugate Development</h5>
                        <p>
                            Selected antibodies from our screens are being developed into antibody-drug conjugates 
                            (ADCs) in collaboration with pharmaceutical partners. This approach allows for targeted 
                            delivery of potent cytotoxic agents while minimizing systemic toxicity.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">PhageDisplay</span>
                        <span class="tech-tag">Antibody Screening</span>
                        <span class="tech-tag">Target Discovery</span>
                        <span class="tech-tag">ADC Development</span>
                        <span class="tech-tag">Cell Surface Targets</span>
                    </div>
                </div>
            </div>

            <!-- Project B: Mass Spectrometry Analysis -->
            <div class="research-section">
                <h2>Project B: Mass Spectrometry Target Identification</h2>
                <div class="project-card">
                    <h3>Proteomics Analysis of KRAS Inhibition Resistance</h3>
                    <div class="project-description">
                        We use quantitative mass spectrometry to identify proteins that are differentially expressed 
                        in response to KRAS inhibition and during the development of resistance. This proteomics 
                        approach reveals post-translational modifications and protein-level changes that may not 
                        be detected through genomic or transcriptomic analyses.
                    </div>

                    <div class="project-details">
                        <h5>Proteomics Pipeline</h5>
                        <ul class="methodology-list">
                            <li>Quantitative proteomics analysis under various drug concentrations</li>
                            <li>Time-course analysis of protein expression changes during treatment</li>
                            <li>Comparative analysis of sensitive vs. resistant cell populations</li>
                            <li>Post-translational modification analysis (phosphoproteomics, ubiquitinomics)</li>
                            <li>Cell surface proteome enrichment for ADC target identification</li>
                        </ul>
                    </div>

                    <div class="project-details">
                        <h5>Resistance Biomarker Discovery</h5>
                        <p>
                            Our mass spectrometry analysis has identified protein signatures that can predict 
                            resistance to KRAS inhibitors before it becomes clinically apparent. These biomarkers 
                            could enable early intervention with combination therapies to prevent resistance 
                            development.
                        </p>
                    </div>

                    <div class="project-details">
                        <h5>Drug Target Validation</h5>
                        <p>
                            Proteins identified through mass spectrometry are validated as potential drug targets 
                            through functional studies, including CRISPR knockout, overexpression experiments, 
                            and small molecule inhibition. This multi-level validation ensures that identified 
                            targets are therapeutically relevant.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Mass Spectrometry</span>
                        <span class="tech-tag">Quantitative Proteomics</span>
                        <span class="tech-tag">Phosphoproteomics</span>
                        <span class="tech-tag">Biomarker Discovery</span>
                        <span class="tech-tag">Target Validation</span>
                    </div>
                </div>
            </div>

            <!-- Translational Applications -->
            <div class="research-section">
                <h2>Translational Applications</h2>
                <div class="project-card">
                    <h3>From Discovery to Clinical Translation</h3>
                    <div class="project-description">
                        Our drug discovery research is designed with clinical translation in mind. We work closely 
                        with pharmaceutical companies, clinical investigators, and regulatory agencies to ensure 
                        that our discoveries can be rapidly translated into new treatments for patients.
                    </div>

                    <div class="project-details">
                        <h5>Clinical Collaboration</h5>
                        <ul class="methodology-list">
                            <li>Partnership with Revolution Medicines for RMC-6236 clinical trial analysis</li>
                            <li>Collaboration with biotech companies for ADC development</li>
                            <li>Integration with ongoing clinical trials at Dana-Farber</li>
                            <li>Biomarker validation in patient samples</li>
                            <li>Regulatory guidance for companion diagnostic development</li>
                        </ul>
                    </div>

                    <div class="impact-highlight">
                        <h4>Patient Impact</h4>
                        <p>
                            Several targets and biomarkers identified through our research are now being tested 
                            in clinical trials. This direct translational pathway ensures that our discoveries 
                            can rapidly benefit pancreatic cancer patients, who have limited treatment options 
                            and urgent need for new therapeutic approaches.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Key Publications & Patents -->
            <div class="research-section">
                <h2>Publications & Intellectual Property</h2>
                <div class="project-card">
                    <h3>Key Outputs</h3>
                    <div class="project-details">
                        <h5>Manuscripts in Preparation</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>CRISPR screening reveals vulnerabilities in KRAS-driven pancreatic cancer</strong> - Submission planned for Nature Cancer 2025</li>
                            <li><strong>Mechanisms of resistance to pan-RAS inhibition</strong> - Cancer Cell submission 2025</li>
                            <li><strong>PhageDisplay identification of novel ADC targets</strong> - Nature Biotechnology 2025</li>
                            <li><strong>Proteomics-guided combination therapy strategies</strong> - Cell Chemical Biology 2025</li>
                        </ul>
                    </div>

                    <div class="project-details">
                        <h5>Patent Applications</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>Novel ADC targets in pancreatic cancer</strong> - Patent application filed 2024</li>
                            <li><strong>Biomarkers for KRAS inhibitor resistance</strong> - Patent application in preparation</li>
                            <li><strong>Combination therapy strategies</strong> - Patent applications filed 2024-2025</li>
                        </ul>
                    </div>

                    <div class="project-details">
                        <h5>Software & Databases</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>CRISPR-Analytics Suite</strong> - Pipeline for CRISPR screen analysis</li>
                            <li><strong>Resistance Predictor</strong> - ML models for resistance prediction</li>
                            <li><strong>ADC Target Database</strong> - Curated database of cell surface targets</li>
                            <li><strong>Drug Combination Optimizer</strong> - Tools for rational combination design</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- Future Directions -->
            <div class="research-section">
                <h2>Future Directions</h2>
                <div class="impact-highlight">
                    <h4>Next-Generation Drug Discovery</h4>
                    <p>
                        We are expanding our drug discovery efforts to include AI-driven approaches for target 
                        identification and drug design. By integrating our CRISPR screening and proteomics data 
                        with machine learning models, we can predict novel drug targets and optimize combination 
                        therapies before experimental validation, accelerating the translation of discoveries 
                        to patient care.
                    </p>
                </div>
            </div>

            <!-- Back Navigation -->
            <div class="text-center" style="margin-top: 3rem;">
                <a href="../index.html#research" class="btn btn-secondary">Back to Research Overview</a>
            </div>
        </div>
    </div>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <div class="footer-content">
                <div class="footer-logo">
                    <h3>Cristea Lab</h3>
                    <p>Computational Cancer Research</p>
                </div>
                <div class="footer-links">
                    <a href="https://www.dana-farber.org" target="_blank">Dana-Farber Cancer Institute</a>
                    <a href="https://www.harvard.edu" target="_blank">Harvard University</a>
                </div>
                <div class="footer-social">
                    <a href="#" class="social-link"><i class="fab fa-twitter"></i></a>
                    <a href="#" class="social-link"><i class="fab fa-github"></i></a>
                    <a href="#" class="social-link"><i class="fab fa-linkedin"></i></a>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2024 Cristea Lab. All rights reserved.</p>
            </div>
        </div>
    </footer>

    <script src="../script.js"></script>
</body>
</html>